MaaT Pharma plans late-2027 first-in-human trial of MaaT034 with PD-(L)1 inhibitors in solid tumors

• MaaT Pharma set an FDA pre-IND meeting for October 2026 to advance MaaT034 into clinical development, with emphasis on manufacturing controls.
• Preclinical results were already presented at AACR and SITC meetings, supporting plans to move into human testing.
• A first-in-human study was designed to establish dosing and generate early proof-of-concept in solid tumors alongside PD-(L)1 inhibitors.
• Initial targets include second-line advanced NSCLC and refractory advanced melanoma, aiming to improve response to immunotherapy in resistant disease.
• Trial start is projected for late 2027, contingent on funding and regulatory clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maat Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202609211300BIZWIRE_USPR_____20260921_BW576057) on September 21, 2026, and is solely responsible for the information contained therein.